When tested as a therapeutic agent against neurodegenerative diseases, C-PE was effective at fighting Alzheimer’s disease (AD) symptoms, such as muscle paralysis, in a dose-dependent manner, after supplementation with C. elegans, via an interaction with the beta-site amyloid precursor protein cleaving enzyme-1 (BACE1) [129]. This evidence concerns the gene BACE1 and early-onset autosomal dominant Alzheimer disease.